[{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Not Applicable"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGF A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Xbrane Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xbrane Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"STADA Arzneimittel \/ BAUSCH + LOMB","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzneimittel \/ BAUSCH + LOMB"},{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"OPT-302","moa":"VEGF C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Samsung Bioepis"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Lake Bleu Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"AffaMed Therapeutics \/ Lake Bleu Capital","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Lake Bleu Capital"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Novartis"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"Axantia Group","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JORDAN","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Axantia Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Axantia Group \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Axantia Group \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"Polpharma","sponsor":"MS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma \/ MS Pharma"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"OPT-302","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"Polpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Bioeq","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Bioeq"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Samsung Bioepis"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Midas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Midas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Bioeq IP AG","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Bioeq IP AG"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Brand Institute"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Polpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polpharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Polpharma \/ Not Applicable"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioeq IP AG \/ Coherus Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Bioeq IP AG \/ Coherus Biosciences"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioeq IP AG \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"Bioeq IP AG \/ Formycon"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Bioeq","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Bioeq"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Xbrane Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"STADA Arzneimittel \/ Xbrane Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Xbrane Biopharma"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"OPT-302","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Not Applicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Undisclosed"},{"orgOrder":0,"company":"Eyconis","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Eyconis","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Eyconis \/ Ascendis Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Eyconis \/ Ascendis Pharma"},{"orgOrder":0,"company":"Opthea","sponsor":"Carlyle Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Opthea \/ Carlyle Group","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Carlyle Group"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Divestment","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Sandoz"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Midas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Midas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Divestment","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Sandoz"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Ranibizumab
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
